April 2017

New Product - Enstilar

Enstilar (calcipotriol, betamethasone) is indicated in the topical treatment of psoriasis vulgaris in adults. It is contraindicated in erythrodermic and pustular psoriasis. Due to the content of calcipotriol, Enstilar is contraindicated with known disorders of calcium metabolism. Due to the content of corticosteroid, Enstilar is contraindicated in the following conditions if present in the treatment area: viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds. Enstilar is available as a foam spray containing calcipotriol 50 microgram/g, betamethasone (as dipropionate) 500 microgram/g in a 60 g can.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au